Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mani Foroohar has given his Buy rating due to a combination of factors that indicate a positive outlook for Intellia Therapeutics. The management’s recent disclosure about a Grade 4 liver transaminase elevation in a patient was addressed with detailed information, assuring that the event was not likely caused by the lipid nanoparticle delivery system, as the timing of the elevation did not align with typical patterns. The patient’s condition improved without significant liver damage, and the trajectory mirrored a previous case, suggesting a manageable situation.
Furthermore, the company’s enrollment goals remain on track, with plans to recruit over 550 ATTR-CM patients by the end of 2025. Despite concerns that such disclosures might slow enrollment or deter interest, the strong enrollment pace and robust patient interest, as indicated by recent surveys, support a stable outlook. These factors contribute to a reinforced confidence in the company’s fundamentals and growth potential, justifying the Buy rating.
According to TipRanks, Foroohar is an analyst with an average return of -12.7% and a 38.33% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as RegenXBio, CureVac, and Tenaya Therapeutics.
In another report released today, JonesTrading also reiterated a Buy rating on the stock with a $25.00 price target.